Cat. #153237
Tafazzin KO Mouse
Cat. #: 153237
Sub-type: Mouse
Availability: 6-8 weeks
Disease: Barth Syndrome
Model: Conditional KO
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Douglas Strathdee
Institute: Cancer Research UK, Glasgow: The Beatson Institute
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Tool name: Tafazzin KO Mouse
- Alternate name: Taz1; G4.5; TAZ1; CMD3A; EFE2; LVNCX; EFE; XAP-2; BTHS; 3-Methylglutaconic aciduria type II
- Research fields: Cell signaling and signal transduction;Genetics;Immunology;Tissue-specific biology
- Tool sub type: Mouse
- Disease: Barth Syndrome
- Model: Conditional KO
- Conditional: Yes
- Description: Barth syndrome is a rare X-linked genetic disorder which affects multiple body systems and is almost exclusively only diagnosed in males. The syndrome is characterized by a weakened and enlarged heart, skeletal myopathy, recurrent infections due to neutropenia and short physical stature. Dilated cardiomyopathy associated with Barth syndrome is often present at birth or develops within the first months of life. The heart muscle gradually weakens and becomes less capable to pump blood around the vasculature. Tafazzin (Taz), a protein encoded by the Taz gene in humans functions as a phospholipid-lysophospholipid transacylase. It is highly expressed in cardiac and skeletal muscle and involved in the metabolism of cardiolipin, a mitochondrial specific phospholipid.
- Zygosity: Homozygous knock out of Taz gene
- Strain: C57BL/6
- Production details: Cre-mediated recombination excises several introns and exons from the Taz gene
- Breeding information: Good breeder - knockout males are sterile
- Additional notes: HM-1 embryonic stem cells were used to construct this mouse model.
Target Details
- Target: Tafazzin (Taz) Gene
